130 results on '"Cirstea, D"'
Search Results
2. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
3. A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
4. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
5. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
6. Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
7. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
8. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
9. Ascorbic acid inhibits antitumor activity of bortezomib in vivo
10. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
11. Unraveling the Synergism of Nab-Rapamycin and Perifosine Combination in Multiple Myeloma: B469
12. A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma: B483
13. Targeting Myeloma Bone Disease via Activin A Inhibition: B357
14. A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease: B203
15. WC-Cu electrical contacts developed by spark plasma sintering process
16. Prediction of precipitate evolution and martensite transformation in Ti-Ni-Cu shape memory alloys by computational thermodynamics
17. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
18. Fatty acid synthase is a novel therapeutic target in multiple myeloma
19. CSNK1α1 mediates malignant plasma cell survival
20. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
21. The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma (MM).
22. B483 A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma
23. B203 A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease
24. B469 Unraveling the Synergism of Nab-Rapamycin and Perifosine Combination in Multiple Myeloma
25. B357 Targeting Myeloma Bone Disease via Activin A Inhibition
26. Recensement des cas de sclérodermie systémique dans une région française : premiers résultats de l’étude ESSYL
27. Shape memory alloys for MEMS components made by powder metallurgy processes
28. Présentation atypique des hémopathies malignes : penser au frottis sanguin
29. Pleiotropic activity of the novel cyclin-dependent kinase inhibitor RGB 286638 predicts therapeutic potential in multiple myeloma
30. Novel therapeutic targets for multiple myeloma.
31. Future novel single agent and combination therapies.
32. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France.
33. Advanced high strength steel (Ahss) alloys processed by powder metallurgy techniques
34. Ascorbic acid inhibits antitumor activity of bortezomib in vivo
35. Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.
36. Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study.
37. Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma.
38. Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System.
39. Treatment disparities in minority groups with multiple myeloma at a safety-net hospital.
40. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.
41. Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.
42. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.
43. Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
44. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
45. Role of decorin in multiple myeloma (MM) bone marrow microenvironment.
46. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.
47. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
48. Estimating the prevalence of systemic sclerosis in the Lorraine region, France, by the capture-recapture method.
49. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
50. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.